Gilead Sciences Inc

Latest stories

1d
FOX Business
Wait On The DNC Before Going Long Biotech ETFsof big-name biotech earnings scheduled to roll in, but the Democratic National
Wait On The DNC Before Going Long Biotech ETFs
FOX Business / Posted yesterday
of big-name biotech earnings scheduled to roll in, but the Democratic National Convention is taking place in Philadelphia. Gilead Sciences, Inc. (NASDAQ:GILD) got the earnings ball rolling after Monday's close and investors weren't pleased by the... Read more
1d
FOX Business
Wait On The DNC Before Going Long Biotech ETFsscheduled to roll in, but the Democratic National Convention is taking place in
Wait On The DNC Before Going Long Biotech ETFs
FOX Business / Posted yesterday
scheduled to roll in, but the Democratic National Convention is taking place in Philadelphia. Continue Reading Below Gilead Sciences, Inc. (GILD) got the earnings ball rolling after Monday's close and investors weren't pleased by the... Read more
1d
Zero Hedge
USDJPY Plunges On Japan Stimulus Concerns; US Futures Flat With As Fed Begins MeetingS&P 500 futures were basically unchanged, down 0.1% after falling Monday from
USDJPY Plunges On Japan Stimulus Concerns; US Futures Flat With As Fed Begins Meeting
Zero Hedge / Posted yesterday
S&P 500 futures were basically unchanged, down 0.1% after falling Monday from last week’s record-high close. Gilead Sciences Inc. fell 4.4 Yields on 10-year Treasury notes fell for the first time in three days, sliding three basis... Read more
2d
FOX Business
Gilead Shares Drop As Drug Maker Cuts Product Sales OutlookShares of Gilead Sciences Inc. declined in Monday's extended session after the
Gilead Shares Drop As Drug Maker Cuts Product Sales Outlook
FOX Business / Posted 2 days ago
Shares of Gilead Sciences Inc. declined in Monday's extended session after the biopharmaceutical company lowered its 2016 outlook on product sales despite turning in better-than-expected quarterly earnings. Gilead reported its second-quarter earnings... Read more
7 related stories
2d
FOX Business
Gilead Shares Drop As Drug Maker Cuts Product Sales OutlookShares of Gilead Sciences Inc. declined in Monday's extended session after the
Gilead Shares Drop As Drug Maker Cuts Product Sales Outlook
FOX Business / Posted 2 days ago
Shares of Gilead Sciences Inc. declined in Monday's extended session after the biopharmaceutical company lowered its 2016 outlook on product sales despite turning in better-than-expected quarterly earnings. Gilead reported its second-quarter earnings... Read more
7 related stories
2d
Market Watch
Gilead shares drop as drug maker cuts product sales outlookShares of Gilead Sciences Inc. GILD, +2.31% declined in Monday's extended sessi
Gilead shares drop as drug maker cuts product sales outlook
Market Watch / Posted 2 days ago
Shares of Gilead Sciences Inc. GILD, +2.31% declined in Monday's extended session after the biopharmaceutical company lowered its 2016 outlook on product sales despite turning in better-than-expected quarterly earnings. Gilead reported its... Read more
7 related stories
2d
Market Watch
Gilead sales of hepatitis C drugs fall 19%Gilead Sciences Inc. said its revenue from its hepatitis C drugs continued to f
Gilead sales of hepatitis C drugs fall 19%
Market Watch / Posted 2 days ago
Gilead Sciences Inc. said its revenue from its hepatitis C drugs continued to fall, dropping 19% during the second quarter, with sales of Harvoni missing expectations as competition from rival drugs and pricing pressures intensified. Shares of the... Read more
7 related stories
2d
Business Wire
Gilead Sciences Announces Third Quarter 2016 DividendFOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) toda
Gilead Sciences Announces Third Quarter 2016 Dividend
Business Wire / Posted 2 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared a cash dividend of $0.47 per share of common stock for the third quarter of 2016. The dividend is payable on... Read more
2d
Business Wire
Gilead Sciences Announces Second Quarter 2016 Financial ResultsFOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) anno
Gilead Sciences Announces Second Quarter 2016 Financial Results
Business Wire / Posted 2 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter ended June 30, 2016. The financial results that follow represent a year-over-year comparison of second quarter... Read more
6d
Roll Call
Aviation, Drug Pricing Keep Lobbyists Busy in Election Yearthe country's major pharmaceutical companies also spent more on K Street this q
Aviation, Drug Pricing Keep Lobbyists Busy in Election Year
Roll Call / Posted 6 days ago
the country's major pharmaceutical companies also spent more on K Street this quarter, including Pfizer Inc.; AbbVie Inc.; Gilead Sciences Inc.; AstraZeneca PLC; Novartis International AG; and Merck & Co. Inc. Together, those companies spent more... Read more
6d
News-Medical-Net
Study provides new insights into real-world use of PrEPas the dawn of the global PrEP era,” said Linda-Gail Bekker, President-elect of
Study provides new insights into real-world use of PrEP
News-Medical-Net / Posted 6 days ago
as the dawn of the global PrEP era,” said Linda-Gail Bekker, President-elect of the International AIDS Society and Principal Investigator at the Desmond Tutu HIV Centre. “A primary focus of this conference is moving science into practice, and... Read more
16 related stories
8d
Boston Globe
Jounce to get $225 million in Celgene dealrequests. With a market value of $79.6 billion, Celgene is the third-largest U
Jounce to get $225 million in Celgene deal
Boston Globe / Posted 8 days ago
requests. With a market value of $79.6 billion, Celgene is the third-largest US biotech company, after Amgen Inc. and Gilead Sciences Inc. Its senior vice president of business development, George Golumbeski, is known as one of the most... Read more
5 related stories
9d
Business Wire
Gilead Sciences to Release Second Quarter 2016 Financial Results on Monday, July 25, 2016FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) anno
Gilead Sciences to Release Second Quarter 2016 Financial Results on Monday, July 25, 2016
Business Wire / Posted 9 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2016 financial results will be released on Monday, July 25, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management... Read more
9d
Accounting Today
Gilead Seen Cutting Taxes by $10 Billion as Pricey Drug Took Off(Bloomberg) Gilead Sciences Inc.’s profit margin has soared and its tax rate ha
Gilead Seen Cutting Taxes by $10 Billion as Pricey Drug Took Off
Accounting Today / Posted 9 days ago
(Bloomberg) Gilead Sciences Inc.’s profit margin has soared and its tax rate has plummeted since the drugmaker introduced its controversial $1,000-a-day medication for hepatitis C, according to a report by an advocacy group that accuses the company... Read more
13d
Calgary Sun
Health Canada approves drug doctors call cure for hepatitis C infectionin Canada is set at $60,000 for a 12-week course -- or more than $700 per pill.
Health Canada approves drug doctors call cure for hepatitis C infection
Calgary Sun / Posted 13 days ago
in Canada is set at $60,000 for a 12-week course -- or more than $700 per pill. Two other hepatitis C drugs also made by Gilead Sciences Inc., and already approved in Canada -- Harvoni (genotype 1) and Sovaldi (genotypes 1, 2 and 3) -- also carry... Read more
2 related stories
13d
The Globe and Mail
Health Canada approves drug doctors call cure for hepatitis C infectionU.S., the drug costs $900 (U.S.) a pill — or almost $75,000 for a 12-week cours
Health Canada approves drug doctors call cure for hepatitis C infection
The Globe and Mail / Posted 13 days ago
U.S., the drug costs $900 (U.S.) a pill — or almost $75,000 for a 12-week course. Two other hepatitis C drugs also made by Gilead Sciences Inc. and already approved in Canada — Harvoni (genotype 1) and Sovaldi (genotypes 1, 2 and 3) — also carry... Read more
2 related stories
14d
Boston Globe
Gilead dodges nearly $10 billion in US taxesThanks to a pair of pricey hepatitis C treatments, Gilead Sciences Inc. has bec
Gilead dodges nearly $10 billion in US taxes
Boston Globe / Posted 14 days ago
Thanks to a pair of pricey hepatitis C treatments, Gilead Sciences Inc. has become one of the world’s largest drug makers. Since 2013, revenues have tripled to more than $32 billion and profits grew sixfold, exceeding $18 billion. But beyond... Read more
2 related stories
14d
The Hill
Freedom Caucus moves to impeach IRS chief | Calls for US-UK trade talks | Clinton ally offers trade for Trump tax returnstax havens, a report released Wednesday by the liberal-leaning Americans for Ta
Freedom Caucus moves to impeach IRS chief | Calls for US-UK trade talks | Clinton ally offers trade for Trump tax returns
The Hill / Posted 14 days ago
tax havens, a report released Wednesday by the liberal-leaning Americans for Tax Fairness (ATF) found. As profits at Gilead Sciences Inc. have skyrocketed in recent years, its tax rate has dropped steeply, according to the report. "Despite... Read more
14d
CTV News
Health Canada approves drug doctors call cure for hepatitis C infectionthe U.S., the drug costs US$900 a pill -- or almost $75,000 for a 12-week cours
Health Canada approves drug doctors call cure for hepatitis C infection
CTV News / Posted 14 days ago
the U.S., the drug costs US$900 a pill -- or almost $75,000 for a 12-week course. Two other hepatitis C drugs also made by Gilead Sciences Inc. and already approved in Canada -- Harvoni (genotype 1) and Sovaldi (genotypes 1, 2 and 3) -- also carry... Read more
2 related stories
14d
FOX Business
Buybacks Pump Up Stock Rallysoon," said David Goss, managing director and head of proprietary strategies at
Buybacks Pump Up Stock Rally
FOX Business / Posted 14 days ago
soon," said David Goss, managing director and head of proprietary strategies at money manager Boston Private Wealth LLC. Gilead Sciences Inc. spent the most in the first quarter, at $8 billion, while Apple Inc. executed $6.7 billion of... Read more
14d
FOX Business
Buybacks Pump Up Stock Rallymanaging director and head of proprietary strategies at money manager Boston Pr
Buybacks Pump Up Stock Rally
FOX Business / Posted 14 days ago
managing director and head of proprietary strategies at money manager Boston Private Wealth LLC. Continue Reading Below Gilead Sciences Inc. spent the most in the first quarter, at $8 billion, while Apple Inc. executed $6.7 billion of... Read more
16d
Jacksonville Daily Record
Bar Bulletin: New proportionality requirements limit scope of discovery in federal casesthat �it is good enough to hope that the information sought might lead to the d
Bar Bulletin: New proportionality requirements limit scope of discovery in federal cases
Jacksonville Daily Record / Posted 16 days ago
that �it is good enough to hope that the information sought might lead to the discovery of admissible evidence.� See Gilead Sciences Inc. v.�Merck & Co. Inc., (N.D. Cal. Jan. 13, 2016). Consistent with this, the committee notes now provide... Read more
19d
Business Wire
Ligand Enters into OmniAb® Platform License Agreement with Gilead SciencesSAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
Ligand Enters into OmniAb® Platform License Agreement with Gilead Sciences
Business Wire / Posted 19 days ago
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with Gilead Sciences, Inc. Under the license, Gilead will be able to use the OmniRat®, OmniMouse® and OmniFlic®... Read more
21d
News-Medical-Net
PREVAIL IV trial opens in Liberia for EVD survivors with persistent traces of Ebola virus RNAof the National Institutes of Health, in partnership with the Ministry of Healt
PREVAIL IV trial opens in Liberia for EVD survivors with persistent traces of Ebola virus RNA
News-Medical-Net / Posted 21 days ago
of the National Institutes of Health, in partnership with the Ministry of Health of Liberia and the pharmaceutical company Gilead Sciences. The six-month study will enroll 60 to 120 EVD survivors whose semen has evidence of Ebola virus RNA prior to... Read more
2 related stories
22d
Business Insurance
Hold middlemen's feet to the fire to cauterize specialty drug spendingare used to treat diseases such as cancer, hepatitis C and rheumatoid arthritis
Hold middlemen's feet to the fire to cauterize specialty drug spending
Business Insurance / Posted 22 days ago
are used to treat diseases such as cancer, hepatitis C and rheumatoid arthritis. Many specialty drugs are pricey: Epclusa, Gilead Sciences Inc.'s hepatitis C drug that the U.S. Food and Drug Administration approved last week, comes to market at... Read more
27d
examiner.com
First quarter share buybacks are near record levels, but is it a good thing?in the first quarter. The total was second only to the $172 billion spent in th
First quarter share buybacks are near record levels, but is it a good thing?
examiner.com / Posted 27 days ago
in the first quarter. The total was second only to the $172 billion spent in the third quarter of 2007. Companies increased first quarter share repurchases by 12% over those in the first quarter of 2015. Although a very large amount was... Read more
29d
CBS News
FDA approves first pill to treat all types of hepatitis Cwith over $18 billion in global sales, according to IMS Health. Sovaldi ranked
FDA approves first pill to treat all types of hepatitis C
CBS News / Posted 29 days ago
with over $18 billion in global sales, according to IMS Health. Sovaldi ranked eighth, pulling in $6.6 billion in sales. Shares of Gilead Sciences Inc., which is based in Foster City, California, rose $4.06, or 5.2 percent, to $82.31 on... Read more
67 related stories
29d
Jefferson City News Tribune
FDA approves first pill to treat all forms of hepatitis Cwith over $18 billion in global sales, according to IMS Health. Sovaldi ranked
FDA approves first pill to treat all forms of hepatitis C
Jefferson City News Tribune / Posted 29 days ago
with over $18 billion in global sales, according to IMS Health. Sovaldi ranked eighth, pulling in $6.6 billion in sales. Shares of Gilead Sciences Inc., which is based in Foster City, California, rose $4.06, or 5.2 percent, to $82.31 on... Read more
67 related stories
29d
Philly.com
FDA approves first pill to treat all forms of hepatitis Cwith over $18 billion in global sales, according to IMS Health. Sovaldi ranked
FDA approves first pill to treat all forms of hepatitis C
Philly.com / Posted 29 days ago
with over $18 billion in global sales, according to IMS Health. Sovaldi ranked eighth, pulling in $6.6 billion in sales. Shares of Gilead Sciences Inc., which is based in Foster City, California, rose $4.06, or 5.2 percent, to $82.31 on... Read more
67 related stories
29d
The Signal
FDA approves first pill to treat all forms of hepatitis Cwith over $18 billion in global sales, according to IMS Health. Sovaldi ranked
FDA approves first pill to treat all forms of hepatitis C
The Signal / Posted 29 days ago
with over $18 billion in global sales, according to IMS Health. Sovaldi ranked eighth, pulling in $6.6 billion in sales. Shares of Gilead Sciences Inc., which is based in Foster City, California, rose $4.06, or 5.2 percent, to $82.31 on... Read more
67 related stories
29d
Orange County Register
FDA approves first pill to treat all forms of hepatitis Cin the world with over $18 billion in global sales, according to IMS Health. So
FDA approves first pill to treat all forms of hepatitis C
Orange County Register / Posted 29 days ago
in the world with over $18 billion in global sales, according to IMS Health. Sovaldi ranked eighth, pulling in $6.6 billion in sales. Shares of Gilead Sciences Inc., which is based in Foster City, rose $4.06, or 5.2 percent, to $82.31 on T... Read more
67 related stories
29d
Silicon Valley
FDA approves first pill to treat all forms of hepatitis Cover $18 billion in global sales, according to IMS Health. Sovaldi ranked eight
FDA approves first pill to treat all forms of hepatitis C
Silicon Valley / Posted 29 days ago
over $18 billion in global sales, according to IMS Health. Sovaldi ranked eighth, pulling in $6.6 billion in sales. Shares of Gilead Sciences Inc., which is based in Foster City, California, rose $3.16, or 4 percent, to $81.41 in afternoon tra... Read more
67 related stories
29d
WDIO Duluth
FDA Approves First Pill to Treat All Forms of Hepatitis C$18 billion in global sales, according to IMS Health. Sovaldi ranked eighth, pu
FDA Approves First Pill to Treat All Forms of Hepatitis C
WDIO Duluth / Posted 29 days ago
$18 billion in global sales, according to IMS Health. Sovaldi ranked eighth, pulling in $6.6 billion in sales. Shares of Gilead Sciences Inc., which is based in Foster City, California, rose $4.06, or 5.2 percent, to $82.31 on... Read more
67 related stories
29d
The Mercury News
FDA approves first pill to treat all forms of hepatitis Cover $18 billion in global sales, according to IMS Health. Sovaldi ranked eight
FDA approves first pill to treat all forms of hepatitis C
The Mercury News / Posted 29 days ago
over $18 billion in global sales, according to IMS Health. Sovaldi ranked eighth, pulling in $6.6 billion in sales. Shares of Gilead Sciences Inc., which is based in Foster City, California, rose $3.16, or 4 percent, to $81.41 in afternoon tra... Read more
67 related stories
29d
Sun-Sentinel
FDA approves first pill to treat all forms of hepatitis C$18 billion in global sales, according to IMS Health. Sovaldi ranked eighth, pu
FDA approves first pill to treat all forms of hepatitis C
Sun-Sentinel / Posted 29 days ago
$18 billion in global sales, according to IMS Health. Sovaldi ranked eighth, pulling in $6.6 billion in sales. Shares of Gilead Sciences Inc., which is based in Foster City, California, rose $3.16, or 4 percent, to $81.41 in afternoon... Read more
67 related stories
29d
The Columbian
FDA approves first pill to treat all forms of hepatitis Cover $18 billion in global sales, according to IMS Health. Sovaldi ranked eight
FDA approves first pill to treat all forms of hepatitis C
The Columbian / Posted 29 days ago
over $18 billion in global sales, according to IMS Health. Sovaldi ranked eighth, pulling in $6.6 billion in sales. Shares of Gilead Sciences Inc., which is based in Foster City, California, rose $3.16, or 4 percent, to $81.41 in afternoon tra... Read more
67 related stories
29d
Providence Business News
U.S. stocks rebound as worries ease after two-day Brexit selloffUtilities, raw materials and consumer staples were little changed. Biotechnolo
U.S. stocks rebound as worries ease after two-day Brexit selloff
Providence Business News / Posted 29 days ago
Utilities, raw materials and consumer staples were little changed. Biotechnology shares led the rally in health-care, with Gilead Sciences Inc. jumping 4 percent, the most in almost five months. Regulators approved Gilead’s hepatitis C drug for all... Read more
13 related stories
29d
The Record Searchlight
FDA approves first pill to treat all forms of hepatitis Cover $18 billion in global sales, according to IMS Health. Sovaldi ranked eight
FDA approves first pill to treat all forms of hepatitis C
The Record Searchlight / Posted 29 days ago
over $18 billion in global sales, according to IMS Health. Sovaldi ranked eighth, pulling in $6.6 billion in sales. Shares of Gilead Sciences Inc., which is based in Foster City, California, rose $3.16, or 4 percent, to $81.41 in afternoon tra... Read more
67 related stories
29d
Your Hometown Lima Stations
FDA approves first pill to treat all forms of hepatitis C$18 billion in global sales, according to IMS Health. Sovaldi ranked eighth, pu
FDA approves first pill to treat all forms of hepatitis C
Your Hometown Lima Stations / Posted 29 days ago
$18 billion in global sales, according to IMS Health. Sovaldi ranked eighth, pulling in $6.6 billion in sales. Shares of Gilead Sciences Inc., which is based in Foster City, California, rose $3.16, or 4 percent, to $81.41 in afternoon... Read more
67 related stories
29d
Market Watch
Gilead receives approval for cheaper hepatitis C drugGilead Sciences Inc. received U.S. Food and Drug Administration approval for it
Gilead receives approval for cheaper hepatitis C drug
Market Watch / Posted 29 days ago
Gilead Sciences Inc. received U.S. Food and Drug Administration approval for its Epclusa hepatitis C combination drug and priced the treatment below its older drugs for the disease. Shares of the Foster City, Calif., company, which dominates the... Read more
67 related stories
29d
WFTV 9 Orlando
FDA approves first pill to treat all forms of hepatitis Cover $18 billion in global sales, according to IMS Health. Sovaldi ranked eight
FDA approves first pill to treat all forms of hepatitis C
WFTV 9 Orlando / Posted 29 days ago
over $18 billion in global sales, according to IMS Health. Sovaldi ranked eighth, pulling in $6.6 billion in sales. Shares of Gilead Sciences Inc., which is based in Foster City, California, rose $3.16, or 4 percent, to $81.41 in afternoon tra... Read more
67 related stories
29d
Los Angeles Times
FDA approves first pill to treat all forms of hepatitis Chave reshaped treatment of the liver-destroying virus. The Food and Drug Admin
FDA approves first pill to treat all forms of hepatitis C
Los Angeles Times / Posted 29 days ago
have reshaped treatment of the liver-destroying virus. The Food and Drug Administration approved the combination pill from Gilead Sciences Inc. for patients with and without liver damage. The agency has approved a number of hepatitis C drugs in... Read more
67 related stories
30d
Boston Globe
Harvard Pilgrim adds new drugs under ‘pay-for-performance dealslast year, it became the first regional health insurer to negotiate a discount
Harvard Pilgrim adds new drugs under ‘pay-for-performance deals
Boston Globe / Posted 30 days ago
last year, it became the first regional health insurer to negotiate a discount of a costly hepatitis C drug made by Gilead Sciences Inc. That contract, which was not outcomes-based, has saved Harvard Pilgrim and its customers between $5... Read more

People in this news